Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).

Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).

Abstract: The present invention relates to an improved process for determining ?-secretase activity and for detecting ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase. In particular, the present invention relates to processes for the identification of a ?-secretase or of a cDNA which codes for a ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase. Another embodiment of the present invention relates to processes for the identification of substances which can inhibit the activity of ?-secretase, or a ?-secretase-like proteinase.

Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).

Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceutical compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

Abstract: A non-human animal model is provided, particularly a mouse model for movement hyperactivity, excitoxicity disorders (e.g. myoclonic cramping) and neurodegeneration, in which modified cytoplasmic dynein heavy chain1 is expressed. Modified human and mouse cytoplasmic dynein heavy chain1 proteins and nucleic adds are also provided, including the corresponding recombinant proteins. The invention further provides uses for the non-human animal model and the modified cytoplasmic dynein heavy chain1 proteins and nucleic acids, in particular for the diagnosis and treatment of medical conditions associated with over-expression of cytoplasmic dynein heavy chain1.

Abstract: The invention relates to a process for the determination of the ?-secretase activity, individual components of the process and the use of the process. The present invention relates to a novel process for the determination of the ?-secretase activity and for the detection of ?-secretase; particular embodiments of the process relate on the one hand to processes for the identification of a ?-secretase or of a cDNA which codes for a ?-secretase and on the other hand to processes for the identification of substances which can inhibit the activity of a ?-secretase. Such substances have particular importance, as they can be used, for example, as pharmaceutical active compounds, e.g. for the treatment of Alzheimer's disease.

Abstract: The present invention relates to an improved process for determining ?-secretase activity and for detecting ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase; particular embodiments of the process relate on the one hand to processes for the identification of a ?-secretase or of a cDNA which codes for a ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase, and on the other hand to processes for the identification of substances which can inhibit the activity of a ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase.

Abstract: The present invention relates to a transgenic C. elegans which expresses an amyloid precursor protein (APP) or a part thereof, to the transgene itself, to the protein encoded by the transgene, and also to a process for preparing the transgenic C. elegans and to its use.

Abstract: The present invention relates to a transgenic C. elegans which expresses an amyloid precursor protein (APP) or a part thereof, to the transgene itself, to the protein encoded by the transgene, and also to a process for preparing the transgenic C. elegans and to its use.

Abstract: The invention relates to a process for the determination of the &ggr;-secretase activity, individual components of the process and the use of the process.